GU Cancers Symposium 2020

Complete Coverage

Longer Survival Seen With Sipuleucel-T Use in mCRPC

In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.